Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2023 09:33 ET | Source: Research and Markets

Adalimumab Global Market Report 2022: Rising Prevalence of Arthritis and Clinical Trials to Spur Growth

Dublin, Feb. 22, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028: Segmented By Type (Biologics v/s Biosimilars), By...
April 29, 2022 18:32 ET | Source: 180 Life Sciences Corp.

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 monthsThe treatment arm...
January 12, 2021 07:03 ET | Source: Research and Markets

Global Crohn's Disease Forecast and Market Analysis Report 2020-2027 - Despite Formulary Constraints, Novel Pipeline Drugs will Expand the Market

Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Crohn's Disease Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering. As specialty products, therapies...
November 18, 2020 09:00 ET | Source: Enosi Life Sciences

Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001

SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enosi Life Sciences Corp. (“Enosi” or the “Company”), a drug research and development company focused on providing industry-leading therapeutics for...
January 08, 2015 02:00 ET | Source: Dermira, Inc.

Dermira and UCB Announce Start of Phase 3 Program for CIMZIA(R) (certolizumab pegol) in Psoriasis

Phase 3 program aims to address patient need for alternative treatment options in moderate-to-severe psoriasis Program includes the first Phase 3 study in psoriasis comparing two...